Análisis de la acción Corcept Therapeutics Inc (CORT)CORTCorcept Therapeutics Inc

Corcept Therapeutics Incorporated is a commercial-stage company. The Company is engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol. It is also conducting advanced clinical trials in patients with solid tumors, Amyotrophic Lateral Sclerosis (ALS) and liver disease. It operates through the discovery, development and commercialization of the pharmaceutical products segment. It sells Korlym and a generic version of Korlym in the United States using sales representatives to call on physicians caring for patients with hypercortisolism (Cushing’s syndrome). The Company's portfolio of selective cortisol modulators consists of four series totaling approximately 1,000 compounds. It sells and distributes Lifyorli in the United States. It is developing its proprietary, selective cortisol modulator, relacorilant, as a treatment for patients with hypercortisolism. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).

Corcept Therapeutics Inc is currently priced at $113.88, with a forward P/E ratio of 60.98 and a gross margin of 98.41%. While the company has shown strong revenue growth, reporting $256.1 million in Q2 2026, the RSI is low at 34.14, indicating potential weakness. The main risk is the recent insider selling, which has increased by 271.06%, suggesting caution among insiders. Overall, while there are positive growth indicators, the current technical weakness and insider activity warrant a hold position for now.

5 analysts cover CORT: 3 rate it Buy, 0 Hold and 2 Sell. The average price target is 91.00.